Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy
- 23 December 2004
- journal article
- Published by Springer Nature in Leukemia
- Vol. 19 (3) , 478
- https://doi.org/10.1038/sj.leu.2403636
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)Leukemia, 2004
- Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaCancer, 2003
- Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received FludarabineJournal of Clinical Oncology, 2002
- Cytomegalovirus Viremia During Campath-1H Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia and Prolymphocytic LeukemiaClinical Lymphoma, 2002
- Valganciclovir: A New Oral Alternative for Cytomegalovirus Retinitis in Human Immunodeficiency Virus-Seropositive IndividualsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
- CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.Journal of Clinical Oncology, 1998